By inhibiting the NLRP3 inflammasome, β-HB diminishes the inflammatory microenvironment, which provides ancillary therapeutic benefits for therapeutic interventions in glioblastoma.238 Interestingly, GPR109A, a receptor for β-HB, is downregulated in cancer. This evidence concerns the gene HCAR2 and cancer.